Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss.  GLP-1 medications were originally intended to ...

Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss ... 2021 to December 2023, of which 58.9% were female. The overall prevalence of discontinuation of GLP-1 ...

Novo Nordisk (NYSE:NVO)'s new weight loss drug CagriSema missed the company's ... which has been available since 2021. Novo Nordisk then introduced CagriSema that is basically an upgrade version ...

Another big one is muscle loss. A new ... weight loss,” Gerhart-Hines said. He explained that GLP-1 agonists don’t work quite as well for weight loss in people with diabetes because the drug ...

Compounded by the equally sudden banning of the weight loss drug, phen-fen (phentermine-fenfluramine ... there remained no new promising pharmaceutical agents addressing obesity.

The U.S.-listed shares of Novo Nordisk A.S. were plunging toward their worst day in decades on Friday after the results from a late-stage trial showed that the Danish company’s new weight-loss ...